After wrestling with the Sandoz problem for several years, Vas Narasimhan settles on a spinout
Novartis CEO Vas Narasimhan has finally figured out how he can get Sandoz off his list of major headaches. He’s going to spin the generics giant out as a separate company.
The pharma giant says it will set up Sandoz as an independent company in H2 2023 after navigating the separation through regulators. The spinout will create a lumbering giant with a home on the SIX Swiss Exchange, an American Depositary Receipt program in the US, a pipeline of 15 biosimilars and a rep for mediocre performance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.